Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcus Biosciences (RCUS) Operating Margin (2017 - 2025)

Historic Operating Margin for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to 546.15%.

  • Arcus Biosciences' Operating Margin fell 3274000.0% to 546.15% in Q3 2025 from the same period last year, while for Sep 2025 it was 156.25%, marking a year-over-year decrease of 353400.0%. This contributed to the annual value of 127.91% for FY2024, which is 1626900.0% up from last year.
  • According to the latest figures from Q3 2025, Arcus Biosciences' Operating Margin is 546.15%, which was down 3274000.0% from 5.0% recorded in Q2 2025.
  • Arcus Biosciences' Operating Margin's 5-year high stood at 79.25% during Q4 2021, with a 5-year trough of 825.87% in Q3 2021.
  • Its 5-year average for Operating Margin is 338.75%, with a median of 286.21% in 2023.
  • Within the past 5 years, the most significant YoY rise in Arcus Biosciences' Operating Margin was 17881200bps (2021), while the steepest drop was -8282800bps (2021).
  • Quarter analysis of 5 years shows Arcus Biosciences' Operating Margin stood at 79.25% in 2021, then crashed by -375bps to 217.65% in 2022, then crashed by -35bps to 293.55% in 2023, then tumbled by -35bps to 396.15% in 2024, then plummeted by -38bps to 546.15% in 2025.
  • Its Operating Margin stands at 546.15% for Q3 2025, versus 5.0% for Q2 2025 and 435.71% for Q1 2025.